艾昆纬-2023年全球药品使用情况（英）-2023-58页_1mb

Global Use of Medicines 2023: Outlook to 2027 Report Summary

Key Findings Overview

• The post-pandemic era has brought clarity to global medicine spending trends, returning to pre-pandemic growth rates by 2024.
• COVID-19 spending exceeded initial projections by $497B through 2027, but its impact is expected to fade sooner.
• Specialty medicines (biologics, cancer treatments) will represent nearly half of spending in developed markets by 2027.

Impact of COVID-19

• Global Spending: $497B cumulative spending increase through 2027 + higher vaccination rates than pre-predicted.
• Vaccines: Spending projected at $380B vs. earlier estimates ($251B), driven by higher doses.
• Long-COVID: Affects 10–20% of infected individuals, requiring ongoing healthcare.

Spending and Growth by Region

• Asia-Pacific, Latin America, and pharmerging markets grow fastest at 2–5% CAGR; Eastern Europe is hampered by Ukraine conflict.
• Advanced economies (Western Europe, US, Japan) see slower growth due to maturity of health systems.
• Ukraine spending could drop 20–30% for three years if conflict persists.

Key Therapy Areas

• Oncology (growth rate 13–16%) and obesity treatments (35–38% CAGR) lead growth.
• Immunology growth will slow due to biosimilar competition.
• Biotech will account for 35% of spending by 2027.

COVID-19 Legacy 2024–2027

• Spending returns to pre-pandemic trajectories with minimal disruptions by 2024.
• Uncertainty from inflation, geopolitical conflicts, and vaccine hesitancy remains key risks.
  </think>Aitken, M. (2023). Global Use of Medicines 2023: Outlook to 2027. IQVIA Institute for Human Data Science.

(Note: Summary extracted from the report's markdown content provided earlier; simulation does not re-generate figures or visualizations.)